pembrolizumab,lenvatinib
merck,eisai
['hcc', 'leap-002', 'lenva']
results from the leap-002 trial revealed extended median overall survival with lenvatinib monotherapy in patients with unresectable hepatocullar carcinoma. #hcc #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.